5th Edition of
International Vaccines Congress
Scientific Program
About
We are delighted to announce the successful conclusion of the 5th Edition of the International Vaccines Congress (IVC 2025), held from October 23–25, 2025, in the vibrant city of Orlando, Florida, USA. The congress brought together a distinguished gathering of vaccine researchers, immunologists, public health experts, pharmaceutical professionals, and policymakers from across the globe to exchange insights and advancements in vaccine development, delivery, and global immunization strategies. Over the course of three impactful days, participants engaged in keynote sessions, plenary discussions, workshops, and poster presentations that showcased pioneering research and practical innovations shaping the future of vaccinology. IVC 2025 served as a collaborative platform fostering knowledge sharing, networking, and interdisciplinary dialogue aimed at addressing global health challenges and strengthening preventive medicine. The passion, expertise, and active participation of attendees made this edition a resounding success.
Scientific Committee Members
Khursheed Nadeem Anwer
Imunon Inc., United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United StatesSpeakers
David Craig Wright
D4 Labs, LLC, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Jesse Kuiper
Merck Research Laboratories, United States
Ying Wan
Merck & Co., United StatesGallery
Reviews
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, Imunon Inc., United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom